In This Section

Stand Up To Cancer Research Teams

Stand Up To Cancer Research Teams are typically smaller than SU2C Dream Teams, but have the same overarching goal of pursuing the most promising research, accelerating the discovery of new therapies for cancer patients and/or advancing efforts in cancer prevention research.

In 2017, SU2C established three Research Teams, two focused on “interception” of cancer at its earliest stages, and one on new uses for CAR T-cell therapy.

In 2014, SU2C announced the SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team to focus on patients with HPV-driven cancers (including anal, cervical, and head and neck cancers).

The first team to receive a Translational Cancer Research Grant, beginning in 2013, in collaboration with the Dutch Cancer Society (DCS), included researchers from the three largest cancer centers in the Netherlands: the Netherlands Cancer Institute, Erasmus MC, and UMC Utrecht. It focused on DNA-guided personalized cancer treatments.

2017 Research Teams

SU2C-Lustgarten Foundation Pancreatic Cancer Interception Translational Research Team: Developing Novel Approaches to Treat and Evaluate Early Pancreatic Cancer

Leader: David P. Ryan, MD, Massachusetts General Hospital
Co-leader: Alec C. Kimmelman, MD, PhD, New York University Langone Health
Grant Term: January 2018 – December 2021 Total Funding: $2.6 million

SU2C-LUNGevity-American Lung Association Lung Cancer Interception Research Team: Blood-Based Early Interception of Lung Cancer

Leader: Lecia V. Sequist, MD, Massachusetts General Hospital
Co-leader: Maximilian Diehn, MD, PhD, Stanford University
Grant Term: December 2017 – November 2018 Total Funding: $2 million

SU2C-Lustgarten Foundation Chimeric Antigen Receptor T Cell (CAR T) Research Team: Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer

Leader: Carl H. June, MD, University of Pennsylvania
Co-leader: Shelley L. Berger, PhD, University of Pennsylvania
Co-leader: John Wherry, PhD, University of Pennsylvania
Grant Term: April 2017 – March 2018 Total Funding: $2 million

2014 Research Team

SU2C-Farrah Fawcett Foundation Translational Team: Therapeutic CD8 Vaccines Against Conserved E7 HPV Epitopes Identified by MS

Leader: Ellis L. Reinherz, MD, Dana-Farber Cancer Institute
Co-leader: Robert I. Haddad, MD, Dana-Farber Cancer Institute
Grant Term: July 2014 – June 2017 Total Funding: $1.2 million


The following teams have completed their projects.  Details of their work are available on the Stand Up To Cancer website.

SU2C-Dutch Cancer Society Team: Prospective Use of DNA-guided Personalized Cancer Treatment Leader: Emile E. Voest, MD, PhD, University Medical Center Utrecht in the Netherlands [Current institution: The Netherlands Cancer Institute]
Co-leader: René Bernards, PhD, The Netherlands Cancer Institute
Grant Term: April 2014 – March 2018 Total Funding: €1.2 million

Contact Information

Email: [email protected] (for non-media related SU2C questions)

Updated: April 1, 2020